Sales Hours: Mon-Fri, 9am to 5pm ET
Currently we only offer two SKUs – incentive spirometer and nasal cannula. Each product meets industry standards and compliance.
PRACSNS – Breakthrough Innovation
Clinical trial pending.
Conventional hemodialysis for Kidney failure requires long hospital/clinic visits three times per week, is highly prone to infection, hospitalization, and costs payers roughly USD $40K to $80 K per patient each year.
With more than three million people on dialysis—and millions more who lack access—renal replacement is overdue for a patient‑friendly alternative.
Patients on dialysis experience weakness and various health issues over time.
Over 8 years, our research has shown there is currently no other alternative to Dialysis except Transplant.
PRACSNS has come out with an innovative concept – Catalytic Biodegradable Microbots that need clinical validation and we are setting up our Clinical Advisory Board to reach pig/porcine trials in 9 months, and subsequently human trial in 30 months.
Oral Treatment. No Dialysis machine required. No surgery required. Toxins and fluids removed cleanly.
Benchtop results meet ISO 10993-4 and ASTM F756.
This breakthrough is subject to Clinical trials, validation, and regulatory approvals.